February 24, 2023 – Novel Claudin 18.2-targeting therapy inching closer to approval in gastric cancer
Positive results reported by Astellas Pharma regarding its novel Claudin 18.2-targeting antibody, zolbetuximab, suggest that an approval in front-line gastric and gastroesophageal junction (GEJ) adenocarcinoma is not far off. Two Phase III studies, SPOTLIGHT (NCT03504397) and GLOW (NCT03653507), examined the efficacy of monoclonal antibody zolbetuximab in patients deemed to have high expression of Claudin 18.2 (characterised as more than 75% of tumour cells with moderate to high expression, as measured by immunohistochemical assay) versus traditional chemotherapy (FOLFOX6 in SPOTLIGHT and CAPOX in GLOW).